CLY-124 Sickle Cell

Learn More

News, Press, & Publications

News, Press, Publications, & Presentations

Sort by year

Reset
Article Types
Reset

Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes. Science, 2025

11.17.25

Publication

Read Article
https://www.science.org/stoken/author-tokens/ST-3021/full

Cellarity Publishes Groundbreaking Framework for Predicting Drug Safety in Nature Communications

11.13.25

Press

Read Article

A large-scale human toxicogenomics resource for drug-induced liver injury prediction. Nature Communications, 2025.

11.13.25

Publication

Read Article

Cellarity Announces Two Oral Presentations During the 67th American Society of Hematology Annual Meeting

10.31.25

Press

Read Article

Cellarity Publishes Framework for Discovery of Cell State-Correcting Medicines in Science

10.23.25

Press

Read Article

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

06.25.25

Press

Read Article

Ted Myles Joins Cellarity as Chief Executive Officer

05.12.25

Press

Read Article

Biotech2050 Podcast: Cellarity CEO Fabrice Chouraqui on how AI/ML are Revolutionizing Drug Discovery

08.28.24

Media

Read Article

Cellarity Appoints Percy Carter, MBA, Ph.D., as Member of Board of Directors

07.25.24

Press

Read Article

Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation

05.07.24

Press

Read Article
Load More